Enzyme-Immobilized Nanomaterials for Endocrine Disorders: Therapeutic Innovation and Translational Challenges.
- 1Department of Ultrasound Medicine, The Second Hospital of Jilin University, Changchun, Jilin, 130000, People's Republic of China.
- 2Department of Radiotherapy, The Second Hospital of Jilin University, Changchun, Jilin, 130000, People's Republic of China.
- 3Department of Endocrinology and Metabolism, The Second Hospital of Jilin University, Changchun, 130000, People's Republic of China.
Abstract
Endocrine disorders result from chronic disturbances in the hormonal regulation and feedback control, which cause metabolic, reproductive, and systemic complications. Despite the advances in disease management with current therapies such as hormone replacement or multi-pathway pharmacological therapies, problems with variable patient response, side effects and the need for continuous monitoring and dose adjustment remain. To overcome some of these limitations, enzyme-immobilized nanomaterials have become attractive platforms for providing controlled biochemical interactions, catalytic activity and enzyme stability for therapeutic and diagnostic purposes. Enzymes can be immobilized using adsorption, covalent binding, cross-linking and entrapment to minimize denaturation, enhance reusability and improve operational performance. At the nanoscale level, other advantages of having high surface area and tunable interfacial chemistry are the better orientation of the enzyme, mass transfer and control over enzyme activity. There are other benefits for magnetic and field responsive nanomaterials in recovery, re-use, scalable processing and regenerable biosensing systems. In this review, the therapeutic potential of enzyme-immobilized nanomaterials for endocrine diseases has been discussed, focusing on the concepts of nanobiocatalyst design, biosensing for endocrine diseases, and the promise of biomanufacturing in the same field. It also points to some of the main hurdles facing the clinical translation of these technologies, such as problems with enzyme leaching, diffusion limitations, loss of interfacial activity, reproducibility issues, long-term stability, and safety evaluation requirements.
Related
- Dynamic three-dimensional chromatin remodeling in lung disease: mechanistic principles, pathogenic regulatory networks, and translational challenges
- HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges
- Engineering extracellular vesicles for inflammatory bowel disease and colitis-associated colorectal cancer: from therapeutic innovation to clinical translation
- Targeting Metabolic Drivers of Cardiovascular Disease: Insights for Therapeutic Innovation.
- Gene therapy for non-obstructive azoospermia: therapeutic avenues and translational pathway to clinical application
BibTeX
@article{zhang2026enzymeimmobilized,
title = {{Enzyme-Immobilized Nanomaterials for Endocrine Disorders: Therapeutic Innovation and Translational Challenges.}},
author = {Bingya Zhang and Jun Zhang and Yangfang He},
journal = {International journal of nanomedicine},
year = {2026},
month = nov,
doi = {10.2147/ijn.s607705},
url = {https://europepmc.org/article/MED/42999627},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Enzyme-Immobilized Nanomaterials for Endocrine Disorders: Therapeutic Innovation and Translational Challenges.
AU - Bingya Zhang
AU - Jun Zhang
AU - Yangfang He
PY - 2026
DA - 2026/11/03
JO - International journal of nanomedicine
DO - 10.2147/ijn.s607705
UR - https://europepmc.org/article/MED/42999627
AB - Endocrine disorders result from chronic disturbances in the hormonal regulation and feedback control, which cause metabolic, reproductive, and systemic complications. Despite the advances in disease management with current therapies such as hormone replacement or multi-pathway pharmacological therapies, problems with variable patient response, side effects and the need for continuous monitoring and dose adjustment remain. To overcome some of these limitations, enzyme-immobilized nanomaterials have become attractive platforms for providing controlled biochemical interactions, catalytic activity and enzyme stability for therapeutic and diagnostic purposes. Enzymes can be immobilized using adsorption, covalent binding, cross-linking and entrapment to minimize denaturation, enhance reusability and improve operational performance. At the nanoscale level, other advantages of having high surface area and tunable interfacial chemistry are the better orientation of the enzyme, mass transfer and control over enzyme activity. There are other benefits for magnetic and field responsive nanomaterials in recovery, re-use, scalable processing and regenerable biosensing systems. In this review, the therapeutic potential of enzyme-immobilized nanomaterials for endocrine diseases has been discussed, focusing on the concepts of nanobiocatalyst design, biosensing for endocrine diseases, and the promise of biomanufacturing in the same field. It also points to some of the main hurdles facing the clinical translation of these technologies, such as problems with enzyme leaching, diffusion limitations, loss of interfacial activity, reproducibility issues, long-term stability, and safety evaluation requirements.
SN - 1176-9114
SN - 1178-2013
ER -